Get started
Author

Genevieve Bergendahl

Observed names: Bergendahl, Genevieve, G. Bergendahl, Genevieve M. Bergendahl
Observed institutions: Hershey (United States), Van Andel Institute, Spectrum Health, Levine Cancer Institute, Levine Children's Hospital, Helen DeVos Children's Hospital, Penn State Health Children's Hospital, Penn State Milton S. Hershey Medical Center
ORCID: 0000-0002-2014-762X
Observed ORCID: 0000-0002-2014-762X
OpenAlex ID: A5032496658
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma
2015 · Giselle L. Saulnier Sholler, Eugene W. Gerner, et al. · PLoS ONE · 143
PDF
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
2018 · Giselle L. Saulnier Sholler, William Ferguson, et al. · Scientific Reports · 108
PDF
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score–Matched Survival Outcome Comparisons
2023 · Javier Oesterheld, William Ferguson, et al. · Journal of Clinical Oncology · 71
PDF
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastoma
2020 · Elizabeth C. Lewis, Jacqueline M. Kraveka, et al. · International Journal of Cancer · 61
PDF
A Phase 1 Study of Nifurtimox in Patients With Relapsed/Refractory Neuroblastoma
2010 · Giselle L. Saulnier Sholler, Genevieve M. Bergendahl, et al. · Journal of Pediatric Hematology/Oncology · 50
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma
2015 · Deanna Mitchell, Genevieve Bergendahl, et al. · Pediatric Blood & Cancer · 32
Feasibility of implementing molecular‐guided therapy for the treatment of patients with relapsed or refractory neuroblastoma
2015 · Giselle L. Saulnier Sholler, Jeffrey P. Bond, et al. · Cancer Medicine · 29
PDF
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma
2022 · Giselle Saulnier-Sholler, Dan G. Duda, et al. · Clinical Cancer Research · 24
PDF
Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma
2017 · Albert Cornelius, Jessica Foley, et al. · Frontiers in Pharmacology · 18
PDF
A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma
2012 · Giselle L. Saulnier Sholler, William Ferguson, et al. · Journal of Cancer Therapy · 18
PDF
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial
2024 · Giselle L. Saulnier Sholler, Genevieve Bergendahl, et al. · Genome Medicine · 14
PDF
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma
2023 · Don Eslin, Peter E. Zage, et al. · International Journal of Cancer · 10
PDF
A pilot study of genomic‐guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high‐risk neuroblastoma
2022 · Jacqueline M. Kraveka, Elizabeth C. Lewis, et al. · Cancer Reports · 5
PDF
Matched external control analysis of event-free survival (EFS) in patients with high-risk neuroblastoma (HRNB) receiving eflornithine (DFMO) maintenance.
2022 · Javier E. Oesterheld, Genevieve Bergendahl, et al. · Journal of Clinical Oncology · 2
Abstract LB-179: Phase I trial of relapsed neuroblastoma with DFMO alone and in combination with etoposide.
2013 · Giselle L. Sholler, Eugene W. Gerner, et al. · Cancer Research · 2
Phase I trial of TPI 287 as a single agent and in combination with temozolomide (TMZ) in patients with refractory or recurrent neuroblastoma (NB) or medulloblastoma (MB).
2011 · G. L. Saulnier Sholler, D. Eslin, et al. · Journal of Clinical Oncology · 2
Abstract CT271: Clinical trial in progress: BCC021 Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors
2026 · Chandrika Behura, Genevieve Bergendahl, et al. · Cancer Research · 1
Survival outcomes in patients with high-risk neuroblastoma (HRNB) in remission after relapsed or refractory treatment receiving eflornithine (DFMO) maintenance.
2024 · Giselle Linda Saulnier Sholler, William Ferguson, et al. · Journal of Clinical Oncology · 1
Data from Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
2023 · Sara A. Byron, William P.D. Hendricks, et al. · 1
Abstract CT015: A phase 1 dose escalation study of TB-403 in pediatric relapsed or refractory medulloblastoma, neuroblastoma, Ewing sarcoma, or alveolar rhabdomyosarcoma
2021 · Giselle L. Saulnier Sholler, Dan G. Duda, et al. · Cancer Research · 1
Ther-21. Targeting Lin28 With Dfmo in Patients With Etmr Suggests Clinical Benefit
2019 · Deanna Mitchell, Mary Durston, et al. · Neuro-Oncology · 1
PDF
A phase I trial of TPI-287 as a single agent and its combination with temozolomide in relapsed neuroblastoma or medulloblastoma.
2010 · G. L. Saulnier Sholler, G. Bergendahl, et al. · Journal of Clinical Oncology · 1
Abstract CT272: Clinical trial in progress: BCC022 a phase II trial of tipifarnib and naxitamab for relapsed/refractory neuroblastoma
2026 · Valerie Brown, Hong-Gang Wang, et al. · Cancer Research
Abstract CT270: Clinical trial in progress: BCC020 a dose escalation study using difluoromethylornithine (DFMO) and AMXT-1501 followed by a randomized controlled trial of DFMO with or without AMXT-1501 for neuroblastoma, CNS tumors, and sarcomas
2026 · Giselle Saulnier Sholler, Genevieve Bergendahl, et al. · Cancer Research
ETMR-04. A case series targeting LIN28 in Embryonal Tumor with Multilayered Rosettes (ETMR) using eflornithine (DFMO)
2025 · Derek Hanson, Abigail Moore, et al. · Neuro-Oncology Pediatrics
Works count: 52
Citation count: 595
H-index: 11
I10-index: 12
Year
Topic
Type